Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Patient Preference and Adherence|October 11, 2021
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database AnalysisGang Li, Alexander Keenan, Mehmet Daskiran, et al.
Psychiatry Research|January 24, 2015
Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness?Ariana Anderson, Marsha Wilcox, Adam Savitz, et al.
JAMA Psychiatry|March 31, 2015
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical TrialJoris Berwaerts, Yanning Liu, Srihari Gopal, et al.
Current Medical Research and Opinion|August 27, 2015
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophreniaSrihari Gopal, An Vermeulen, Partha Nandy, et al.
Arthritis and Rheumatism|July 13, 2002
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusionLarry W Moreland, Rieke Alten, Filip Van den Bosch, et al.
The American Journal of Psychiatry|September 10, 2025
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First ApprovalGerard Sanacora, Muhammad Ahmed, Brianne Brown, et al.
The New England Journal of Medicine|September 16, 2005
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionMark C Genovese, Jean-Claude Becker, Michael Schiff, et al.
Neuropsychiatric Disease and Treatment|September 2, 2017
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Pageof 5